Trissel Lawrence A, Zhang Yanping, Xu Quanyun A
Clinical Pharmaceutics Research, Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Int J Pharm Compd. 2006 May-Jun;10(3):234-6.
The objective of this study was to evaluate the physical and chemical stability of mixtures of undiluted palonosetron hydrochloride 50 micrograms/mL with dacarbazine 4 mg/mL and with methylprednisolone sodium succinate 5 mg/mL in 5% dextrose injection during simulated Y-site administration. Triplicate test samples were prepared by admixing 7.5 mL of palonosetron hydrochloride with 7.5 mL of dacarbazine solution and, separately, methylprednisolone sodium succinate solution. Physical stability was assessed by using a multistep evaluation procedure that included both turbidimetric and particulate measurement as well as visual inspection. Chemical stability was assessed by using stability-indicating high-performance liquid chromatographic analytical techniques that determined drug concentrations. Evaluations were performed immediately after mixing and 1 and 4 hours after mixing. The palonosetron hydrochloride-dacarbazine samples were clear and colorless when viewed in normal fluorescent room light and when viewed with a Tyndall beam. Measured turbidities remained unchanged; particulate contents were low and exhibited little change. High-performance liquid chromatography analysis revealed that palonosetron hydrochloride and dacarbazine remained stable throughout the 4-hour test with no drug loss. Palonosetron hydrochloride is, therefore, physically compatible and chemically stable with dacarbazine during Y-site administration. Within 4 hours, the mixtures of palonosetron hydrochloride and methylprednisolone sodium succinate developed a microprecipitate that became a white precipitate visible to the unaided eye. The precipitate was analyzed and identified as methylprednisolone. Palonosetron hydrochloride is incompatible with methylprednisolone sodium succinate.
本研究的目的是评估在模拟Y型接口给药过程中,50微克/毫升盐酸帕洛诺司琼与4毫克/毫升达卡巴嗪以及5毫克/毫升甲泼尼龙琥珀酸钠在5%葡萄糖注射液中的混合物的物理和化学稳定性。通过将7.5毫升盐酸帕洛诺司琼与7.5毫升达卡巴嗪溶液以及单独的甲泼尼龙琥珀酸钠溶液混合来制备一式三份的测试样品。通过使用包括比浊法和颗粒测量以及目视检查的多步骤评估程序来评估物理稳定性。通过使用测定药物浓度的稳定性指示高效液相色谱分析技术来评估化学稳定性。在混合后立即以及混合后1小时和4小时进行评估。在正常荧光室内光线下以及用廷德尔光束观察时,盐酸帕洛诺司琼-达卡巴嗪样品清澈无色。测得的浊度保持不变;颗粒含量低且变化不大。高效液相色谱分析表明,盐酸帕洛诺司琼和达卡巴嗪在整个4小时的测试中保持稳定,没有药物损失。因此,在Y型接口给药期间,盐酸帕洛诺司琼与达卡巴嗪在物理上相容且化学上稳定。在4小时内,盐酸帕洛诺司琼和甲泼尼龙琥珀酸钠的混合物形成了一种微沉淀,肉眼可见其变成白色沉淀。对沉淀进行分析并鉴定为甲泼尼龙。盐酸帕洛诺司琼与甲泼尼龙琥珀酸钠不相容。